Protillion Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Protillion Biosciences, Inc. - overview
Established
2019
Location
Burlingame, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2019 by David Walt, Curtis Layton (CEO), and Will Greenleaf, Protillion Biosciences, Inc. operates as a biotechnology company that provides the design and development of protein-based drugs with the use of revolutionizing traditional approaches. In December 2022, Protillion Biosciences, Inc. raised USD 18 million in series A funding led by ARCH Venture Partners, with participation from Illumina Ventures.
Protillion Biosciences, Inc. is an operator of bioscience intended to focus on accelerating the selection of protein-based drug candidates while improving their clinical success potential. The company has created a new, powerful, and increased protein display platform that is established to revolutionize traditional methods to protein-based drug design and development. The company plans to use the December 2022 funding to expand its market and support its product development.
Current Investors
ARCH Venture Partners, Illumina Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.protillion.com
Verticals
Research (Non-Medical)
Company Stage
Series A
Total Amount Raised
Subscriber access only
Protillion Biosciences, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.